5 completed, 5 recruiting, 1 terminated. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 5, Recruiting 5, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Prostate Cancer Metastatic: new trials by email Literature Review of Prostate Cancer Metastatic trials Research Report on Prostate Cancer Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) 177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic | Phase 3 | Recruiting | UNICANCER | 500 | 2024-09-12 | 2024-12-20 |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer Stereotactic Ablative Body Radiotherapy (SABR), 177Lu-PSMA-617, Androgen Deprivation Therapy (ADT) - Prostate Cancer Metastatic | Phase 3 | Recruiting | University College, London | 3360 | 2024-06-11 | 2025-09-26 |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Opevesostat, Abiraterone acetate, Enzalutamide - Prostate Cancer Metastatic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1310 | 2023-12-31 | 2026-11-03 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) Darolutamide 300 mg, Placebo, Androgen deprivation therapy - Prostate Cancer Metastatic | Phase 3 | Recruiting | UNICANCER | 300 | 2022-04-19 | 2026-04-28 |
| HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) HC-1119, Enzalutamide - Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 3 | Terminated | Hinova Pharmaceuticals USA, Inc. | 104 | 2021-03-15 | 2024-08-19 |
| Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer 18F-DCFPyL, PET/CT Imaging - Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Completed | Progenics Pharmaceuticals, Inc. | 208 | 2018-11-27 | 2021-06-14 |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel Cabazitaxel, Abiraterone, Enzalutamide - Prostate Cancer Metastatic, Metastasis | Phase 2 / Phase 3 | Completed | The Netherlands Cancer Institute | 100 | 2017-05-07 | 2022-04-15 |
| Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF) - Prostate Cancer Metastatic | Phase 3 | Completed | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 196 | 2017-05-05 | 2022-05-12 |
| A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer PROSTVAC-V, PROSTVAC-F, GM-CSF - Prostate Cancer Metastatic | Phase 3 | Completed | Bavarian Nordic | 1297 | 2011-11-28 | 2019-09-04 |
| Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen CABAZITAXEL - Prostate Cancer Metastatic | Phase 3 | Completed | Sanofi | 984 | 2010-12-01 | 2015-01-21 |
Neoplasm Metastasis (3) · Prostatic Neoplasms (3) · Disease (1) · Genital Diseases, Male (1) · Prostatic Diseases (1)
Genital Diseases (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Urogenital Diseases (4) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Neoplasms by Site (3) · Neoplastic Processes (3) · Prostatic Diseases (3) · Urogenital Neoplasms (3)
Androgen Antagonists (4) · enzalutamide (4) · Prednisone (3) · cabazitaxel (3) · Docetaxel (2) · Pluvicto (2) · Radiosurgery (2) · Radiotherapy (2) · darolutamide (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Abiraterone Acetate (1) · Dexamethasone (1) · Granulocyte Colony-Stimulating Factor (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hydrocortisone (1)
UNICANCER (2) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · Bavarian Nordic (1) · Hinova Pharmaceuticals USA, Inc. (1) · Merck Sharp & Dohme LLC (1) · Progenics Pharmaceuticals, Inc. (1) · Sanofi (1) · The Netherlands Cancer Institute (1) · Universitaire Ziekenhuizen KU Leuven (1) · University College, London (1)
France (6) · Canada (5) · Germany (5) · Netherlands (5) · Spain (5) · United Kingdom (5) · Australia (4) · Belgium (4) · Denmark (4) · Italy (4) · Poland (4) · United States (4) · Austria (3) · Finland (3) · Ireland (3)
James L. Gulley, MD (1) · Jessica D Jensen (1) · Karim Fizazi, MD (1) · Louise Brown (1) · Nick James (1) · Philip Kantoff, MD (1)
PMID 25001524, PMID 25639506, PMID 30817251, PMID 33463373, PMID 36503429, PMID 37883073, PMID 41732008, PMID 41806372, PMID 42020286
2023 (1)